Geron Announces Preclinical Study Data of GRNCM1

GRNCM1 Exhibits Protective Properties Against Arrhythmias and Halts Cardiac Remodeling in an Acute Injury Model

MENLO PARK, Calif.--(BUSINESS WIRE)--Mar 1, 2011 - Geron Corporation (Nasdaq:GERN) today announced preclinical study data showing positive effects of GRNCM1, Geron's cardiomyocyte product derived from human embryonic stem cells (hESCs), in a small animal model of acute heart damage. Administering GRNCM1 by injection into the heart resulted in greater resistance to induced arrhythmias, halted adverse cardiac remodeling and preserved mechanical function compared to controls. The results suggest that GRNCM1 positively impacts cardiac function through several mechanisms, leading to overall increased cardiac output and decreased arrhythmias in the acute infarct setting. Geron is developing GRNCM1 for the treatment of myocardial disease.

A cardiac arrhythmia is an abnormality of the heart rhythm, which can cause the heart to pump less efficiently. Cardiac remodeling refers to the changes in size, shape and function of the heart after injury, typically due to acute myocardial infarction, which over time results in a decline in function.

The data were presented at the Keystone Symposium on Mechanisms of Cardiac Growth, Death and Regeneration in Keystone, CO, by Geron collaborator Dr. Michael Laflamme from the University of Washington Medical School in Seattle, WA.

“We have previously shown in safety studies using a guinea pig model of chronic cardiac injury that there was no significant difference in the incidence of arrhythmias between recipients of hESC-cardiomyocytes and controls,” said Michael Laflamme, M.D., Ph.D. “Here we used a guinea pig model of acute cardiac injury and found that, compared to controls, recipients of hESC-cardiomyocytes showed fewer induced arrhythmias one month after transplantation. These results are important because following an acute myocardial infarction patients are at an elevated risk of cardiac arrhythmias, which can be fatal.”

“As part of the early safety studies with GRNCM1, we wanted to test whether transplantation of the product would increase the incidence of arrhythmias, which is a potential safety concern for cardiac cellular therapies. We were pleased when the data in the guinea pig chronic injury model showed no increase in cardiac arrhythmias, and are very encouraged to learn now that our product might actually protect against arrhythmias in this acute injury model,” added Jane S. Lebkowski, Geron's senior vice president and chief scientific officer, cell therapies. “The current data also suggest that GRNCM1 halts the remodeling process and preserves cardiac function. We hope to confirm these observations of increased cardiac output in our ongoing study in a swine chronic infarct model.”

A guinea pig model was used to assess the potential for arrhythmias from GRNCM1 because the animal's heart rate and electrophysiology are more similar to humans than other small animal models. Myocardial infarction was induced by cryoinjury. Seven days after injury, GRNCM1 was administered into the heart. Control groups received either non-cardiac cells derived from hESCs or vehicle only. Thirty days after administering the cells, a technique called programmed electrical stimulation (PES) was used to test the heart's susceptibility to ventricular tachycardia intentionally induced by repeated electrical stimulation of the heart under anesthesia. In the control groups, ventricular tachycardia was induced in 61.5% (8/13) of animals that received non-cardiac cells and 50% (7/14) that received vehicle only. In contrast, ventricular tachycardia was induced in only 6% (1/15) of animals that received GRNCM1, suggesting a protective effect against arrhythmias in this acute model.

Echocardiogram analysis across the experimental groups was performed to assess cardiac function. The results showed statistically significant improvements in left ventricular diastolic diameter (LVDD), left ventricular systolic diameter (LVSD) and fractional shortening (FS) in animals that received GRNCM1 compared to controls. These data indicate that the remodeling process, which leads to the functional decline of the heart after myocardial infarction, might be attenuated by administering GRNCM1 in this model.

Geron is currently conducting studies of GRNCM1 in a swine model of myocardial infarction to further assess preclinical safety and efficacy of the product in an animal model with a cardiovascular system of similar size and structure to humans.

According to the American Heart Association, congestive heart failure, a common consequence of heart muscle or valve damage, affects approximately five million people in the United States and it is estimated that every year about one million people will have a heart attack, which is the primary cause of heart muscle damage.

About Geron

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. The company is advancing anti-cancer therapies through multiple Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and with a compound designed to penetrate the blood-brain barrier. The company is developing cell therapy products from differentiated human embryonic stem cells for multiple indications, including central nervous system (CNS) disorders, heart failure, diabetes and osteoarthritis, and has initiated a Phase 1 clinical trial in spinal cord injury. For more information, visit www.geron.com.

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release regarding potential applications of Geron's human embryonic stem cell technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, the uncertainty and preliminary nature of clinical trial results or regulatory approvals or clearances, need to raise additional capital, dependence upon collaborators and protection of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2010.

 

Contact: Geron Corporation
Anna Krassowska, Ph.D., 650-473-7765
Investor and Media Relations
info@geron.com

 

Posted: March 2011

View comments

Hide
(web2)